Could Dimension Therapeutics IPO Be the Next Wall Street Blockbuster?
It has been a great year for healthcare stocks, with more than 30 biotechnology and pharmaceutical companies filing for an initial public offering (IPO) this year. The latest upcoming IPO making news on the market is a Massachusetts-based biotech company. Here’s everything you need to know about the Dimension Therapeutics IPO before making an investment decision.
What Is Dimension Therapeutics?
Dimension Therapeutics is a biotechnology company involved in discovering and developing gene-therapy products for genetic liver diseases and rare disorders resulting from genetic mutations. It is an emerging growth player in the biotechnology sector within the healthcare industry.
The company’s main product portfolio includes four key gene-therapy candidates: its lead drug for Hemophilia B treatment called “DTX101,” its gene-therapy program for Hemophilia A named “DTX201.” and its two gene-therapy products for patients with Ornithine TransCarbamylase (OTC) deficiency and Glycogen Storage Disease type I, a (GSDIa) deficiency, named “DTX301” and “DTX401.”
The company is headed by Annalisa Jenkins who has formerly served in the c-suites of famous pharmaceutical companies like Merck & Co. and Bristol-Myers Squibb. The company received initial research and development funding from Fidelity Biosciences.
What Is Dimension Therapeutics’ Revenue?
Dimension Therapeutics posted $3.33 million in revenue for the last six months, ending June 2015, which is more than a 1,900% increase from the same period in 2014.
What Is Dimension Therapeutics’ IPO Price?
The IPO price for Dimension Therapeutics’ common stock is expected to range between $14.00 and $16.00 per share.
What Is Dimensions Therapeutics’ IPO Symbol?
The company will get listed on the NASDAQ index under the symbol “DMTX.”
How Much Money Will Dimension Therapeutics’ IPO Raise?
Dimension Therapeutics is expecting an IPO price of $14.00 to $16.00 per share. The company is going to offer 5.5 million shares in total with an over allotment option of 825,000 shares. At an average price of $15.00 for the initial offering of 5.5 million shares, Dimension Therapeutics’ valuation for this offering stands at $82.5 million. The maximum money the company expects to raise is $101.2 million if the shares go public inclusive of the over allotment at the maximum price of $16.00.
How Would Dimension Therapeutics Use the Money?
Dimension Therapeutics intends to use the money for advancing its four key product candidates and to step up its research and development activity. The company spent more than four times the revenue on research and development in the last six months. The money will go towards preparing the products for clinical trials as soon as the end of this year.
What Is Dimension Therapeutics’ IPO Date?
Dimension Therapeutics’ IPO date is set for Monday, October 22.
Where Can You Find More Info on the Company?